US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5766629A
(en)
|
1995-08-25 |
1998-06-16 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US6368586B1
(en)
|
1996-01-26 |
2002-04-09 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US5985312A
(en)
*
|
1996-01-26 |
1999-11-16 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6120806A
(en)
*
|
1997-06-25 |
2000-09-19 |
Whitmire; David R. |
Oral formulations for controlled release of alcohol deterrents
|
FR2775435B1
(fr)
*
|
1998-02-27 |
2000-05-26 |
Bioalliance Pharma |
Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6197340B1
(en)
*
|
1998-05-28 |
2001-03-06 |
Medical Research Institute |
Controlled release lipoic acid
|
US6905707B2
(en)
*
|
1998-05-28 |
2005-06-14 |
Medical Research Institute |
Controlled release arginine alpha ketoglutarate
|
US20050085498A1
(en)
*
|
1998-05-28 |
2005-04-21 |
Byrd Edward A. |
Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
|
US20040259895A1
(en)
*
|
1998-05-28 |
2004-12-23 |
Medical Research Institute |
Oral formulation of lipid soluble thiamine and lipoic acid
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
AU6283299A
(en)
*
|
1998-10-01 |
2000-04-17 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
US6984404B1
(en)
|
1998-11-18 |
2006-01-10 |
University Of Florida Research Foundation, Inc. |
Methods for preparing coated drug particles and pharmaceutical formulations thereof
|
NZ552959A
(en)
|
1998-11-27 |
2008-06-30 |
Darwin Discovery Ltd |
Compositions and methods for increasing bone mineralization
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
EP2000803A1
(de)
|
1998-11-30 |
2008-12-10 |
Nanosphere, Inc. |
Nanoteilchen mit Polymerschalen
|
US20020054914A1
(en)
*
|
1999-02-03 |
2002-05-09 |
Tulin Morcol |
Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
|
US20040258763A1
(en)
*
|
1999-02-03 |
2004-12-23 |
Bell Steve J.D. |
Methods of manufacture and use of calcium phosphate particles containing allergens
|
DK1150918T3
(da)
|
1999-02-03 |
2004-12-20 |
Biosante Pharmaceuticals Inc |
Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
|
US6410255B1
(en)
*
|
1999-05-05 |
2002-06-25 |
Aurora Biosciences Corporation |
Optical probes and assays
|
ATE370928T1
(de)
|
1999-05-14 |
2007-09-15 |
Nereus Pharmaceuticals Inc |
Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren
|
EP1754488A1
(de)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
|
US6406745B1
(en)
*
|
1999-06-07 |
2002-06-18 |
Nanosphere, Inc. |
Methods for coating particles and particles produced thereby
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
RU2155602C1
(ru)
*
|
1999-11-30 |
2000-09-10 |
Оао "Куантум Сатис" |
Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
|
PT1265915E
(pt)
|
2000-02-23 |
2011-02-07 |
Glaxosmithkline Biolog Sa |
Novos compostos
|
JP2003523769A
(ja)
*
|
2000-02-23 |
2003-08-12 |
ヴァーテックス ファーマシューティカルズ (サンディエゴ)エルエルシー |
改変された蛍光タンパク質
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6582713B2
(en)
|
2000-04-06 |
2003-06-24 |
Univ. Of Colorado - Colorado Springs |
Compositions and methods for promoting wound healing
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
CA2309575A1
(en)
*
|
2000-05-26 |
2001-11-26 |
James E. Guillet |
Internally cross-linked macromolecules
|
ATE442866T1
(de)
|
2000-06-20 |
2009-10-15 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
ATE396265T1
(de)
|
2000-06-28 |
2008-06-15 |
Corixa Corp |
Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
|
US6602523B1
(en)
|
2000-08-17 |
2003-08-05 |
Technology Holding, Llc. |
Composite material and process for increasing bioavailability and activity of a beneficial agent
|
AU2002243228B2
(en)
*
|
2000-11-16 |
2007-08-02 |
The Regents Of The University Of California |
Marine actinomycete taxon for drug and fermentation product discovery
|
JP2005500247A
(ja)
*
|
2000-12-07 |
2005-01-06 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
ヒトmda−7に関わる処置方法
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US6607784B2
(en)
*
|
2000-12-22 |
2003-08-19 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20030185892A1
(en)
*
|
2001-08-17 |
2003-10-02 |
Bell Steve J. D. |
Intraocular delivery compositions and methods
|
US20030095928A1
(en)
*
|
2001-09-19 |
2003-05-22 |
Elan Pharma International Limited |
Nanoparticulate insulin
|
IL160570A0
(en)
*
|
2001-09-26 |
2004-07-25 |
Baxter Int |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
ES2405790T3
(es)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
JP2005533000A
(ja)
*
|
2002-03-05 |
2005-11-04 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
Mda−7に関与する免疫誘導を増強する方法
|
AU2003221841A1
(en)
|
2002-04-03 |
2003-10-27 |
Celltech R And D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
WO2003086278A2
(en)
|
2002-04-05 |
2003-10-23 |
Board Of Regents, The University Of Texas System |
Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
EP2269618A1
(de)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Ein onkolytisches Vaccinia-Virus zur Verwendung in Kombination mit Chemotherapie zur Behandlung von Krebs
|
US7112581B2
(en)
*
|
2002-09-27 |
2006-09-26 |
Nereus Pharmaceuticals, Inc. |
Macrocyclic lactams
|
US20050051968A1
(en)
*
|
2002-11-13 |
2005-03-10 |
Froesel David William |
Washer toss game
|
EP1576138B1
(de)
|
2002-11-15 |
2017-02-01 |
Idenix Pharmaceuticals LLC. |
2'-methyl nukleoside in kombination mit interferon und flaviviridae-mutation
|
AU2003301064A1
(en)
*
|
2002-12-17 |
2004-07-14 |
Massachusetts Institute Of Technology |
Stimuli-responsive systems for controlled drug delivery
|
BRPI0406628A
(pt)
|
2003-01-06 |
2005-12-06 |
Corixa Corp |
Determinados compostos de fosfato de aminoalquil glucosaminida e seu uso
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
WO2004067013A1
(en)
*
|
2003-01-24 |
2004-08-12 |
Flora Technology Inc. |
Compositions and methods for restoring bacterial flora
|
WO2004078124A2
(en)
*
|
2003-03-03 |
2004-09-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving mda-7
|
EP1636270B1
(de)
|
2003-06-16 |
2016-07-20 |
UCB Pharma S.A. |
Spezifische antikörper für sclerostin und verfahren zur erhöhung der knochenmineralisierung
|
CN1823070A
(zh)
*
|
2003-06-20 |
2006-08-23 |
加利福尼亚大学董事会 |
盐孢菌酰胺及其使用方法
|
KR20060026052A
(ko)
*
|
2003-06-20 |
2006-03-22 |
니리어스 파마슈티컬즈, 인코퍼레이션 |
암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
|
WO2005007196A2
(en)
|
2003-07-16 |
2005-01-27 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
EP1525890A1
(de)
*
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Protein-Proteophor Komplex
|
WO2005041655A1
(en)
|
2003-10-22 |
2005-05-12 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
|
WO2005082396A2
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
BRPI0506535A
(pt)
*
|
2004-01-23 |
2007-02-27 |
Nereus Pharmaceuticals Inc |
pirroles bis-indole úteis como agentes anti-microbiais
|
CA2555921A1
(en)
*
|
2004-02-13 |
2005-09-15 |
Nod Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of making and using same
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
BRPI0509824A
(pt)
*
|
2004-04-30 |
2007-10-09 |
Nereus Pharmaceuticals Inc |
compostos heterocìclicos [3.2.0] e métodos de uso dos mesmos
|
US7579371B2
(en)
|
2004-04-30 |
2009-08-25 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
EP1766096B1
(de)
|
2004-05-25 |
2013-01-02 |
Oregon Health and Science University |
Hiv-impfung mit impfvektoren auf hcmv-basis
|
WO2006004774A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Stanford University |
Laulimalide analogues as therapeutic agents
|
FR2872703B1
(fr)
*
|
2004-07-07 |
2006-10-06 |
Ethypharm Sa |
Nanoparticules polymeriques composites
|
CN1732962A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
阿霉素-聚氰基丙烯酸正丁脂纳米粒的制备方法
|
CN1733313A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
聚氰基丙烯酸正丁酯纳米颗粒的制备方法
|
JP2008509933A
(ja)
*
|
2004-08-13 |
2008-04-03 |
エミスフェアー・テクノロジーズ・インク |
送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
|
US10583094B2
(en)
|
2004-09-18 |
2020-03-10 |
University Of Maryland |
Therapeutic methods that target the NCCA-ATP channel
|
ATE487484T1
(de)
|
2004-09-18 |
2010-11-15 |
Univ Maryland |
Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
|
US7282194B2
(en)
*
|
2004-10-05 |
2007-10-16 |
Gp Medical, Inc. |
Nanoparticles for protein drug delivery
|
CA2586035A1
(en)
*
|
2004-11-01 |
2006-05-11 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
|
BRPI0517135B1
(pt)
|
2004-12-03 |
2022-04-19 |
Triphase Research And Development I Corp |
Composições e métodos para tratar doenças neoplásticas
|
EP1885746B1
(de)
|
2005-02-08 |
2012-01-11 |
Research Development Foundation |
Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
|
WO2006086798A2
(en)
*
|
2005-02-08 |
2006-08-17 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving mda-7 for the treatment of cancer
|
ES2259914B1
(es)
*
|
2005-03-14 |
2007-06-16 |
Advanced In Vitro Cell Technologies, S.L. |
Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
|
EP2392347A3
(de)
|
2005-03-31 |
2012-01-18 |
GlaxoSmithKline Biologicals S.A. |
Impfstoffe gegen Chlamydieninfektion
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
US8466133B2
(en)
|
2005-04-22 |
2013-06-18 |
University Of Geneva |
Polylactides compositions and uses thereof
|
CN101273055B
(zh)
|
2005-04-29 |
2016-03-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于预防或治疗结核分枝杆菌感染的新方法
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
MX2007015183A
(es)
*
|
2005-06-14 |
2008-02-19 |
Baxter Int |
Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
|
US7893299B2
(en)
|
2005-07-21 |
2011-02-22 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
US20090156480A1
(en)
*
|
2005-08-25 |
2009-06-18 |
Mitsuru Akashi |
Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein
|
KR20090004839A
(ko)
*
|
2005-09-07 |
2009-01-12 |
제네렉스, 인코포레이티드 |
Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
EP2395012B8
(de)
|
2005-11-02 |
2018-06-06 |
Arbutus Biopharma Corporation |
Modifizierte siRNA-Moleküle und Verwendungen davon
|
CA2628630A1
(en)
*
|
2005-11-15 |
2007-05-24 |
Baxter International Inc. |
Compositions of lipoxygenase inhibitors
|
US8883841B2
(en)
|
2005-11-23 |
2014-11-11 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
AU2006318400C1
(en)
|
2005-11-28 |
2013-01-17 |
Gtx, Inc. |
Nuclear receptor binding agents
|
US20090081157A1
(en)
|
2006-01-09 |
2009-03-26 |
Richard Syd Kornbluth |
Immunostimulatory Combinations for Vaccine Adjuvants
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
EP1876188A1
(de)
*
|
2006-07-04 |
2008-01-09 |
NanoDel Technologies GmbH |
Zweistufiges Polymerisationsverfahren in Miniemulsion
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
EP2064229B1
(de)
|
2006-09-15 |
2015-08-12 |
Ottawa Hospital Research Institute |
Onkolytisches rhabdovirus
|
WO2008036776A2
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US8466154B2
(en)
|
2006-10-27 |
2013-06-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
WO2008061013A2
(en)
|
2006-11-10 |
2008-05-22 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
US20100015665A1
(en)
*
|
2006-11-10 |
2010-01-21 |
Ucb Pharma S.A. |
Antibodies and diagnostics
|
US8715653B2
(en)
|
2006-11-21 |
2014-05-06 |
The Regents Of The University Of California |
Modulation of Rhamm (CD168) for selective adipose tissue development
|
US20080138418A1
(en)
*
|
2006-12-07 |
2008-06-12 |
Tong Shen Enterprise Co., Ltd. |
Nanoparticles composed of alkyl-cyanoacrylate polymers
|
WO2008089103A2
(en)
|
2007-01-12 |
2008-07-24 |
University Of Maryland, Baltimore |
Targeting ncca-atp channel for organ protection following ischemic episode
|
US8679539B2
(en)
*
|
2007-01-31 |
2014-03-25 |
Tong Shen Enterprise Co., Ltd. |
Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
|
AU2008214095B2
(en)
|
2007-02-02 |
2014-07-10 |
Baylor College Of Medicine |
Compositions and methods for the treatment of metabolic disorders
|
WO2008095195A2
(en)
*
|
2007-02-02 |
2008-08-07 |
Nereus Pharmaceuticals, Inc. |
Lyophilized formulations of salinosporamide a
|
EP2114160B1
(de)
|
2007-02-09 |
2016-11-16 |
University of Maryland, Baltimore |
Antagonisten eines nicht selektiven kationenkanals in nervenzellen
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
CN101687027B
(zh)
|
2007-04-04 |
2015-01-28 |
传染性疾病研究院 |
包含结核分枝杆菌多肽及其融合的免疫原性组合物
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
PL2152663T3
(pl)
|
2007-06-04 |
2014-09-30 |
Ben Gurion Univ Of The Negev Research And Development Authority |
Związki triarylowe oraz kompozycje zawierające te związki
|
WO2009002832A2
(en)
|
2007-06-22 |
2008-12-31 |
University Of Maryland, Baltimore |
Inhibitors of ncca-atp channels for therapy
|
US20090017167A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Herbalife International Inc. |
Mixture and beverage made therefrom for protecting cellular hydration
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
EP2185196B1
(de)
|
2007-08-27 |
2014-06-11 |
Longhorn Vaccines & Diagnostics, LLC |
Immunogene zusammensetzungen und verfahren
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
NZ584308A
(en)
|
2007-10-01 |
2012-04-27 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection and transport system for nucleic acids and methods of use
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
CA2707400A1
(en)
|
2007-12-14 |
2009-06-25 |
Amgen Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
EP2238251B1
(de)
|
2007-12-27 |
2015-02-11 |
Protiva Biotherapeutics Inc. |
Silencing der polo-like-kinase-expression unter verwendung von interferenz-rna
|
EP2236143A4
(de)
*
|
2007-12-27 |
2011-01-05 |
Public Univ Corp Yokohama City |
Antimikrobiotikum für gram-positive bakterien
|
CA2721380A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Silencing of csn5 gene expression using interfering rna
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
EP2285960B1
(de)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit der mirna-184modulation von neovaskularisation oder angiogenese
|
BRPI0908686B8
(pt)
*
|
2008-05-09 |
2021-05-25 |
South Dakota State Univ |
método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
|
CA2723465A1
(en)
|
2008-05-12 |
2009-11-19 |
Nereus Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US8404471B2
(en)
|
2008-06-26 |
2013-03-26 |
Atyr Pharma, Inc. |
Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
|
WO2010033560A2
(en)
|
2008-09-16 |
2010-03-25 |
University Of Maryland, Baltimore |
Sur1 inhibitors for therapy
|
US8765817B1
(en)
|
2008-12-03 |
2014-07-01 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
US8349899B1
(en)
|
2008-12-03 |
2013-01-08 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
EP2403864B1
(de)
|
2009-02-27 |
2015-08-12 |
Atyr Pharma, Inc. |
Polypeptidstrukturmotive im zusammenhang mit zellsignalisierungsaktivität
|
WO2010107825A2
(en)
|
2009-03-16 |
2010-09-23 |
Pangu Biopharma Limited |
Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
|
CA2757289A1
(en)
|
2009-03-31 |
2010-10-21 |
Atyr Pharma, Inc. |
Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
|
JP2012524818A
(ja)
|
2009-04-24 |
2012-10-18 |
バンダービルト ユニバーシティ |
骨細胞機能および骨成長の抗TGF−βによる誘導法
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
EP2449114B9
(de)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Neue lipidformulierungen zur abgabe von therapiemitteln in feste tumore
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
EP2456304B1
(de)
|
2009-07-24 |
2015-08-19 |
Baylor College Of Medicine |
Verfahren zur modulierung von säuren mit verzweigten ketten und anwendungen davon
|
CA2771769C
(en)
|
2009-08-28 |
2019-10-29 |
Research Development Foundation |
Urocortin 2 analogs and uses thereof
|
CN107303302A
(zh)
|
2009-09-14 |
2017-10-31 |
希拉金股份有限公司 |
溶瘤牛痘病毒组合癌症疗法
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
MX337062B
(es)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Rabdovirus oncolítico.
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
CA2783731C
(en)
|
2009-12-11 |
2018-03-27 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating inflammation
|
EP2512600A2
(de)
|
2009-12-18 |
2012-10-24 |
Amgen Inc. |
Wise-bindemittel und epitope
|
WO2011092253A1
(en)
|
2010-01-27 |
2011-08-04 |
Glaxosmithkline Biologicals S.A. |
Modified tuberculosis antigens
|
EP2560624B1
(de)
|
2010-04-23 |
2018-07-04 |
KemPharm, Inc. |
Therapeutische formulierung für reduzierte medikamenten-nebenwirkungen
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
EP3567106A1
(de)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Auf das zns abzielende aav-vektoren und verfahren zur verwendung davon
|
US9816108B2
(en)
|
2010-04-23 |
2017-11-14 |
University Of Florida Research Foundation, Inc. |
rAAV-guanylate cyclase compositions and methods for treating lebers congenital amaurosis-1 (LCA1)
|
EP2563380B1
(de)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten der cysteinyl-trna-synthetase
|
AU2011248614B2
(en)
|
2010-04-27 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
EP2563383B1
(de)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
WO2011139986A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
CN103140233B
(zh)
|
2010-05-03 |
2017-04-05 |
Atyr 医药公司 |
与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
ES2623805T3
(es)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
|
JP6008844B2
(ja)
|
2010-05-04 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
p38MULTI−tRNA合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CA2799091A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
AU2011252990B2
(en)
|
2010-05-14 |
2017-04-20 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
DK3195880T3
(da)
|
2010-05-14 |
2020-03-02 |
Amgen Inc |
Højkoncentrerede anti-sclerostin-antistofformuleringer
|
CA2799480C
(en)
|
2010-05-17 |
2020-12-15 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
|
EP2575856B1
(de)
|
2010-05-27 |
2017-08-16 |
aTyr Pharma, Inc. |
Therapeutische, diagnostische und antikörperhaltige zusammensetzungen in zusammenhang mit proteinfragmenten von glutaminyl-trna-synthetasen
|
WO2011153277A2
(en)
|
2010-06-01 |
2011-12-08 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
|
WO2012021247A2
(en)
|
2010-07-12 |
2012-02-16 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
EP4050109A1
(de)
|
2010-08-18 |
2022-08-31 |
Fred Hutchinson Cancer Center |
Mittel zur verwendung bei der behandlung von fazioskapulohumeraler dystrophie (fshd)
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
US20120114688A1
(en)
|
2010-11-08 |
2012-05-10 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
KR101942237B1
(ko)
|
2011-01-04 |
2019-01-25 |
신라젠(주) |
종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
|
CA2824235A1
(en)
|
2011-01-11 |
2012-07-19 |
Fate Therapeutics, Inc. |
Novel wnt compositions and therapeutic uses of such compositions
|
WO2012103328A1
(en)
|
2011-01-26 |
2012-08-02 |
The Methodist Hospital Research Institute |
Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use
|
SG192252A1
(en)
|
2011-02-03 |
2013-09-30 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
CN103459598B
(zh)
|
2011-02-03 |
2016-08-10 |
米尔纳医疗股份有限公司 |
Mir-124的合成模拟物
|
US8986739B2
(en)
|
2011-02-28 |
2015-03-24 |
Nicholas V. Perricone |
Treatment of urinary incontinence using nitrone spin traps
|
JP2014509588A
(ja)
|
2011-03-01 |
2014-04-21 |
アムジエン・インコーポレーテツド |
二特異性結合剤
|
SG10201701634PA
(en)
|
2011-03-25 |
2017-04-27 |
Amgen Inc |
Anti - sclerostin antibody crystals and formulations thereof
|
EP2692742A4
(de)
|
2011-03-31 |
2014-10-01 |
Nanocame Co Ltd |
Neues herstellungsverfahren für strukturen höherer ordnung mit antizellwirkung
|
LT3404041T
(lt)
|
2011-04-19 |
2020-08-25 |
Amgen Inc. |
Osteoporozės gydymo būdas
|
EP2718427B1
(de)
|
2011-06-08 |
2017-01-11 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Zusammensetzungen zur behandlung von glioblastomen
|
ES2710452T3
(es)
|
2011-06-10 |
2019-04-25 |
Bluebird Bio Inc |
Vectores de terapia génica para la adrenoleucodistrofia y la adrenomieloneuropatía
|
CN103608030A
(zh)
|
2011-06-21 |
2014-02-26 |
昂科发克特公司 |
用于治疗和诊断癌症的组合物和方法
|
ES2751388T3
(es)
|
2011-07-22 |
2020-03-31 |
Univ Chicago |
IGF-1 para su uso en el tratamiento de la jaqueca
|
ES2667554T3
(es)
|
2011-08-04 |
2018-05-11 |
Amgen Inc. |
Método para el tratamiento de los defectos de espacio óseo
|
WO2013057592A2
(en)
|
2011-09-14 |
2013-04-25 |
King Abdullah University Of Science And Technology |
Treatment of sickle cell disease
|
US9644005B2
(en)
|
2011-09-21 |
2017-05-09 |
King Abdullah University Of Science And Technology |
Didemnin biosynthetic gene cluster in Tistrella mobilis
|
KR101931403B1
(ko)
|
2011-09-23 |
2018-12-21 |
블루버드 바이오, 인코포레이티드. |
개선된 유전자 치료 방법
|
WO2013095736A2
(en)
|
2011-09-27 |
2013-06-27 |
The Methodist Hospital Research Institute |
Gold-in-silicon nanoassembly for thermal therapy and methods of use
|
KR102011532B1
(ko)
|
2011-09-30 |
2019-08-16 |
블루버드 바이오, 인코포레이티드. |
개선된 바이러스 형질도입을 위한 화합물
|
EP2768481A4
(de)
|
2011-10-21 |
2015-07-08 |
Subhash Desai |
Zusammensetzungen zur verringerung von nebenwirkungen
|
AU2012376221A1
(en)
|
2011-10-31 |
2014-06-19 |
David S. Baskin |
Compound comprising a MAO targeting/ seeker moiety for treating human gliomas
|
CN104080797A
(zh)
|
2011-11-11 |
2014-10-01 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
WO2013082476A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
WO2013086433A1
(en)
|
2011-12-07 |
2013-06-13 |
The Methodist Hospital Research Institute |
Sirna compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
SG10201509629QA
(en)
|
2011-12-28 |
2015-12-30 |
Amgen Inc |
Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
|
EP2805617A4
(de)
*
|
2012-01-19 |
2015-08-12 |
Shoichi Shirotake |
Antibakterielles mittel gegen pflanzenbefall verursachende bakterien
|
EP3494989A1
(de)
|
2012-01-26 |
2019-06-12 |
Longhorn Vaccines and Diagnostics, LLC |
Zusammengesetzte antigensequenzen und impfstoffe
|
US20150024037A1
(en)
|
2012-02-16 |
2015-01-22 |
The University Of Toledo |
Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
|
BR112014020824B1
(pt)
|
2012-02-24 |
2022-10-04 |
Protiva Biotherapeutics Inc |
Lipídeo, partícula de lipídeo e composição farmacêutica
|
AR092821A1
(es)
|
2012-04-20 |
2015-05-06 |
Sucampo Ag |
Conjugado de derivado de acido graso-polimero
|
AU2013261214A1
(en)
*
|
2012-05-16 |
2014-11-20 |
Glaxo Group Limited |
Polypeptide loaded POCA nanoparticles for oral administration
|
BR112014027834A2
(pt)
|
2012-05-23 |
2017-08-08 |
Univ Ohio State |
composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso
|
JP6770312B2
(ja)
|
2012-07-05 |
2020-10-14 |
ユセベ ファルマ ソシエテ アノニム |
骨疾患の治療
|
BR112015002483A2
(pt)
|
2012-08-03 |
2017-11-07 |
Infectious Disease Res Inst |
composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
|
US20150258198A1
(en)
*
|
2012-08-14 |
2015-09-17 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
US20150224176A1
(en)
*
|
2012-08-14 |
2015-08-13 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
KR20150136061A
(ko)
|
2013-02-01 |
2015-12-04 |
산타 마리아 바이오테라퓨틱스, 인코포레이티드 |
대상에 항-액티빈-a 화합물의 투여
|
CA2901501C
(en)
|
2013-02-21 |
2023-03-07 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
WO2014160339A1
(en)
|
2013-03-13 |
2014-10-02 |
Board Of Regents, The University Of Texas System |
Compounds for treating inflammatory and hyperproliferative diseases
|
US9909114B2
(en)
|
2013-03-28 |
2018-03-06 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2014186746A1
(en)
|
2013-05-16 |
2014-11-20 |
University Of Florida Research Foundation, Inc. |
HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
|
CN105555757A
(zh)
|
2013-07-23 |
2016-05-04 |
普洛体维生物治疗公司 |
用于递送信使rna的组合物和方法
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
NZ759287A
(en)
|
2013-12-02 |
2022-10-28 |
Baylor College Medicine |
Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
|
US10351644B2
(en)
|
2014-02-27 |
2019-07-16 |
Shoichi Shirotake |
Antiviral drug
|
CA2942078C
(en)
|
2014-03-14 |
2023-03-14 |
The University Of North Carolina At Chapel Hill |
Small molecules for inhibiting male fertility
|
SG11201607795UA
(en)
|
2014-04-08 |
2016-10-28 |
Methodist Hospital |
Inos-inhibitory compositions and their use as breast cancer therapeutics
|
US9693994B2
(en)
|
2014-04-09 |
2017-07-04 |
Research Development Foundation |
Class IIa HDAC inhibitors for the treatment of infection
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
EP3157953B1
(de)
|
2014-06-20 |
2021-12-22 |
Aveo Pharmaceuticals, Inc. |
Behandlung von chronischer nierenerkrankung und anderen nierendysfunktionen mit einem gdf15-modulator
|
WO2015196142A1
(en)
|
2014-06-20 |
2015-12-23 |
Aveo Pharmaceuticals, Inc. |
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
CN107072217A
(zh)
|
2014-09-01 |
2017-08-18 |
中央研究院 |
长寿动物模型和延长寿命与抑制肿瘤发生的方法
|
CN106794986A
(zh)
|
2014-09-02 |
2017-05-31 |
布平德尔·辛格 |
氘化或非氘化分子以及药物制剂
|
CN107208093B
(zh)
|
2014-09-04 |
2022-03-01 |
纪念斯隆-凯特琳癌症中心 |
用于治疗血红蛋白病的球蛋白基因治疗
|
PT3197493T
(pt)
|
2014-09-25 |
2021-06-04 |
Aveo Pharmaceuticals Inc |
Métodos para reverter a caquexia e prolongar a sobrevivência que compreendem a administração de um modulador de gdf15 e um agente anti-carcinogénico
|
AU2015328012A1
(en)
|
2014-10-02 |
2017-05-11 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing Hepatitis B virus gene expression
|
EP3200830B1
(de)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
Hocheffiziente bibliotheksidentifizierte aav-vektoren
|
EP3912620A1
(de)
|
2014-10-08 |
2021-11-24 |
Pacific Northwest Research Institute |
Verfahren und zusammensetzungen zur erhöhung der wirksamkeit von antimykotika
|
US10480011B2
(en)
|
2014-10-21 |
2019-11-19 |
University Of Massachusetts |
Recombinant AAV variants and uses thereof
|
US10302644B2
(en)
|
2014-11-04 |
2019-05-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
WO2016145217A1
(en)
|
2015-03-10 |
2016-09-15 |
The Trustees Of Columbia University In The City Of New York |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
|
WO2016172026A1
(en)
|
2015-04-20 |
2016-10-27 |
The Board Of Regents Of The University Of Texas System |
Clec11a is a bone growth agent
|
US11020443B2
(en)
|
2015-04-23 |
2021-06-01 |
University Of Massachusetts |
Modulation of AAV vector transgene expression
|
EP3294448A4
(de)
|
2015-05-14 |
2018-12-12 |
Longhorn Vaccines and Diagnostics, LLC |
Schnellverfahren zur extraktion von nukleinsäuren aus biologischen proben
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
US10962551B2
(en)
|
2015-06-17 |
2021-03-30 |
The Johns Hopkins University |
TDP-43 in degenerative disease
|
EP3329003A2
(de)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur ausschaltung einer hepatitis-b-virus-genexpression
|
US20170056485A1
(en)
|
2015-08-31 |
2017-03-02 |
Sciotec Diagnostic Technologies Gmbh |
Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
AU2016349632A1
(en)
|
2015-11-07 |
2018-05-24 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
JP2019508063A
(ja)
|
2016-01-27 |
2019-03-28 |
オンコラス, インコーポレイテッド |
腫瘍溶解性ウイルスベクター及びその使用
|
WO2017132321A1
(en)
|
2016-01-29 |
2017-08-03 |
The Johns Hopkins University |
Novel inhibitors of bacterial growth
|
EP3413928B1
(de)
|
2016-02-12 |
2022-04-20 |
University of Massachusetts |
Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut
|
US11040025B2
(en)
|
2016-02-17 |
2021-06-22 |
The Johns Hopkins University |
Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
|
US11149060B2
(en)
|
2016-02-19 |
2021-10-19 |
University Of Delaware |
Functionalized nanoparticles for enhanced affinity precipitation of proteins
|
EP3419602A1
(de)
|
2016-02-22 |
2019-01-02 |
The Methodist Hospital |
Biomimetische proteolipidvesikelzusammensetzungen und verwendungen davon
|
WO2017147370A1
(en)
|
2016-02-24 |
2017-08-31 |
The Johns Hopkins University |
Novel antiviral proteins and their uses in therapeutic methods
|
CN109069440A
(zh)
|
2016-03-02 |
2018-12-21 |
得克萨斯州大学系统董事会 |
用于免疫治疗的激活sting的纳米疫苗
|
IL302398A
(en)
|
2016-03-03 |
2023-06-01 |
Univ Massachusetts |
End-capped linear double-stranded DNA for non-viral gene transfer
|
US10888549B2
(en)
|
2016-03-07 |
2021-01-12 |
The Johns Hopkins University |
Pharmaceutical agents targeting cancer stem cells
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
CA3017143A1
(en)
|
2016-03-10 |
2017-09-14 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
US11965009B2
(en)
|
2016-03-10 |
2024-04-23 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
JP2019510088A
(ja)
|
2016-03-17 |
2019-04-11 |
ザ ジョンズ ホプキンス ユニバーシティーThe Johns Hopkins University |
Parisのファルネシル化によってパーキンソン病を予防または治療する方法
|
EP3436609B1
(de)
|
2016-03-30 |
2022-05-04 |
The Johns Hopkins University |
Olfr90-spezifität und nachweisverfahren
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
US20200148729A1
(en)
|
2016-05-21 |
2020-05-14 |
Infectious Disease Research Institute |
Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
|
EP3478838A1
(de)
|
2016-06-30 |
2019-05-08 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur abgabe von boten-rna
|
JP2019520405A
(ja)
|
2016-07-05 |
2019-07-18 |
ユニバーシティ オブ マサチューセッツ |
緑内障における神経保護療法としてのsFasLのAAV2媒介遺伝子送達
|
AU2017298385A1
(en)
|
2016-07-19 |
2019-03-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic viruses targeting STAT3
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
MX2019003035A
(es)
|
2016-09-16 |
2019-09-13 |
Infectious Disease Res Inst |
Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
US11149275B2
(en)
|
2016-10-10 |
2021-10-19 |
The Johns Hopkins University |
Device and method to treat esophageal disorders
|
US11491114B2
(en)
|
2016-10-12 |
2022-11-08 |
Curioralrx, Llc |
Formulations for enteric delivery of therapeutic agents
|
EP3526333A4
(de)
|
2016-10-13 |
2020-07-29 |
University of Massachusetts |
Aav-capsid-designs
|
KR20190112263A
(ko)
|
2016-12-12 |
2019-10-04 |
멀티비르 인코포레이티드 |
암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
|
US10434089B2
(en)
|
2017-01-25 |
2019-10-08 |
The Johns Hopkins University |
Avibactam and carbapenems antibacterial agents
|
EP4008344B1
(de)
|
2017-01-27 |
2023-12-06 |
The Methodist Hospital |
Kern-hülle-strukturplattform für die immuntherapie
|
US11857516B2
(en)
|
2017-02-12 |
2024-01-02 |
Neuromagen Pharma, Ltd. |
Telomerase activating compounds for use in fertility and related applications
|
AU2018261637A1
(en)
|
2017-05-03 |
2019-12-12 |
Biomarin Pharmaceutical Inc. |
Improved lentiviruses for transduction of hematopoietic stem cells.
|
BR112019025732A2
(pt)
|
2017-06-06 |
2020-06-30 |
University Of Massachusetts |
vetores de aav auto-reguladores para expressão segura de mecp2 na síndrome de rett
|
CN111316099A
(zh)
|
2017-07-12 |
2020-06-19 |
约翰霍普金斯大学 |
用于1型糖尿病诊断的基于脂蛋白体的znt8自身抗原
|
CN111212656A
(zh)
|
2017-07-26 |
2020-05-29 |
昂克诺斯公司 |
溶瘤病毒载体及其用途
|
WO2019028469A1
(en)
|
2017-08-04 |
2019-02-07 |
The Methodist Hospital |
FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
|
US20200276299A1
(en)
|
2017-09-08 |
2020-09-03 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|
EP3710029A4
(de)
|
2017-11-16 |
2021-08-18 |
University of Maine System Board of Trustees |
Zusammensetzungen und verfahren zur modulation der endothelzellmigration und angiogenese
|
WO2019113321A1
(en)
|
2017-12-06 |
2019-06-13 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
WO2019118527A1
(en)
|
2017-12-14 |
2019-06-20 |
The Johns Hopkins University |
Novel anti-fungal inhibitors
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
US20200385758A1
(en)
|
2018-01-05 |
2020-12-10 |
Ottawa Hospital Research Institute |
Modified vaccinia vectors
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
JP2021519065A
(ja)
|
2018-03-23 |
2021-08-10 |
ユニバーシティ オブ マサチューセッツ |
骨障害を処置するための遺伝子治療法
|
CN112533614A
(zh)
|
2018-03-28 |
2021-03-19 |
美国康宝莱国际公司 |
多糖的乙酰化
|
CA3093457A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
WO2019210269A1
(en)
|
2018-04-27 |
2019-10-31 |
University Of Massachusetts |
Aav capsids identified by in vivo library selection
|
JP7253274B2
(ja)
|
2018-05-08 |
2023-04-06 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
Aav適合性ラミニン-リンカー重合タンパク質
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
CA3113470A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Mutant reverse tetracycline transactivators for expression of genes
|
WO2020069373A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
US20220033824A1
(en)
|
2018-11-29 |
2022-02-03 |
University Of Massachusetts |
Modulation of sptlc1 via recombinant adeno-associated vectors
|
EP3908312A2
(de)
|
2019-01-12 |
2021-11-17 |
The Methodist Hospital |
Selbstorganisiertes peptidnanoteilchen und seine verwendung
|
WO2020163766A1
(en)
|
2019-02-07 |
2020-08-13 |
Baylor College Of Medicine |
Periosteal skeletal stem cells in bone repair
|
CA3131023A1
(en)
|
2019-02-22 |
2020-08-27 |
Michael R. Volkert |
Oxr1 gene therapy
|
US11717506B2
(en)
|
2019-05-07 |
2023-08-08 |
The Johns Hopkins University |
Neuroprotective compounds for amyotrophic lateral sclerosis
|
JP2022547305A
(ja)
|
2019-09-13 |
2022-11-11 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
Aav適合性ラミニン-リンカー重合タンパク質
|
CA3157063A1
(en)
|
2019-10-10 |
2021-04-15 |
Oncorus, Inc. |
Dual viruses and dual oncolytic viruses and methods of treatment
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
CN115697388A
(zh)
|
2020-01-30 |
2023-02-03 |
优莫佳生物制药股份有限公司 |
双特异性转导增强子
|
KR20230113689A
(ko)
|
2020-03-31 |
2023-08-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 변이체 및 그의 용도
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
AU2021321944A1
(en)
|
2020-08-07 |
2023-04-06 |
Access To Advanced Health Institute |
Purified saponins and chromatographic process for purification of same
|
EP4255457A1
(de)
|
2020-12-03 |
2023-10-11 |
University of Massachusetts |
Entwicklung von neuen gentherapeutika für fibrodysplasia ossificans progressiva
|
KR20220082558A
(ko)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
|
WO2022164935A1
(en)
|
2021-01-27 |
2022-08-04 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
GB2614309A
(en)
|
2021-12-24 |
2023-07-05 |
Stratosvir Ltd |
Improved vaccinia virus vectors
|
WO2023144393A1
(en)
|
2022-01-28 |
2023-08-03 |
Fundació Centre De Regulació Genòmica |
Therapeutic cytokines and methods
|
WO2023144792A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2023215481A1
(en)
|
2022-05-05 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
|
WO2023225569A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|